The Institute of Cancer Research, London, has hailed the ‘life-changing’ decision by NICE to recommend that the targeted drug olaparib can be used for NHS patients with both early-stage breast cancer and prostate cancer.
Nullam et interdum sapien, eu facilisis erat. Etiam eget quam nisi. Integer imperdiet eros vel lorem pellentesque, non ornare libero aliquam. Phasellus nec urna molestie, pellentesque nisi at, volutpat odio. Mauris pulvinar efficitur neque at pretium. Nunc euismod turpis ante, et porttitor diam auctor sed. Ut erat metus, tincidunt a malesuada nec, blandit ut felis. Nullam pulvinar ac dolor at euismod. Curabitur scelerisque ac urna in cursus. Nulla nisi elit, consectetur a sem ac, laoreet condimentum massa
